DOP2019000228A - COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER - Google Patents

COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER

Info

Publication number
DOP2019000228A
DOP2019000228A DO2019000228A DO2019000228A DOP2019000228A DO P2019000228 A DOP2019000228 A DO P2019000228A DO 2019000228 A DO2019000228 A DO 2019000228A DO 2019000228 A DO2019000228 A DO 2019000228A DO P2019000228 A DOP2019000228 A DO P2019000228A
Authority
DO
Dominican Republic
Prior art keywords
quinolin
compounds
imidazo
cancer
ona
Prior art date
Application number
DO2019000228A
Other languages
English (en)
Inventor
Gordon Pike Kurt
Christophe Barlaam Bernard
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of DOP2019000228A publication Critical patent/DOP2019000228A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La memoria descriptiva se refiere en general a compuestos de Fórmula (I): (I) y sales farmacéuticamente aceptables de estos, donde R1 tiene los significados definidos en la presente. La memoria descriptiva también se refiere al uso de compuestos de Fórmula (I) y sales de estos para tratar o prevenir una enfermedad mediada por ATM, incluido el cáncer. La memoria descriptiva se refiere además a composiciones farmacéuticas que comprenden compuestos de tipo imidazo[4,5-c]quinolin-2-ona sustituidos y sales farmacéuticamente aceptables de estos; y kits que comprenden tales compuestos y sales.
DO2019000228A 2017-03-16 2019-09-06 COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER DOP2019000228A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762472080P 2017-03-16 2017-03-16

Publications (1)

Publication Number Publication Date
DOP2019000228A true DOP2019000228A (es) 2019-09-30

Family

ID=61801891

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2019000228A DOP2019000228A (es) 2017-03-16 2019-09-06 COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER

Country Status (25)

Country Link
US (2) US20200087300A1 (es)
EP (1) EP3596076A1 (es)
JP (1) JP2020514344A (es)
KR (1) KR20190129923A (es)
CN (1) CN110431139B (es)
AU (1) AU2018234985B2 (es)
BR (1) BR112019018723A2 (es)
CA (1) CA3055258A1 (es)
CL (1) CL2019002527A1 (es)
CO (1) CO2019010029A2 (es)
CR (1) CR20190429A (es)
DO (1) DOP2019000228A (es)
EA (1) EA038233B1 (es)
EC (1) ECSP19066134A (es)
IL (1) IL269272A (es)
JO (1) JOP20190209A1 (es)
MA (1) MA49884A (es)
MX (1) MX2019010898A (es)
NI (1) NI201900094A (es)
PE (1) PE20191486A1 (es)
PH (1) PH12019502086A1 (es)
SG (1) SG11201908065YA (es)
TW (1) TW201843151A (es)
UA (1) UA124554C2 (es)
WO (1) WO2018167203A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV15575A (lv) * 2019-12-20 2021-06-20 Latvijas Organiskās Sintēzes Institūts Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
CN116194109A (zh) 2020-06-24 2023-05-30 阿斯利康(英国)有限公司 抗体-药物缀合物和atm抑制剂的组合
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022128833A1 (en) 2020-12-15 2022-06-23 Merck Patent Gmbh Solid transition metal-ligand complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
DK0885198T3 (da) 1996-03-05 2002-03-25 Astrazeneca Ab 4-Anilinoquinazolinderivater
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
CA2763821A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1h-imidazo[4,5-c]quinolinone derivatives
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (es) * 2014-05-08 2018-04-21
ES2946507T3 (es) * 2015-04-02 2023-07-20 Merck Patent Gmbh Imidazolonilquinolinas y su uso como inhibidores de ATM cinasa
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer

Also Published As

Publication number Publication date
CN110431139A (zh) 2019-11-08
CL2019002527A1 (es) 2019-11-22
ECSP19066134A (es) 2019-09-30
AU2018234985A1 (en) 2019-10-24
CO2019010029A2 (es) 2019-09-30
BR112019018723A2 (pt) 2020-04-07
WO2018167203A1 (en) 2018-09-20
UA124554C2 (uk) 2021-10-05
PE20191486A1 (es) 2019-10-18
US20200087300A1 (en) 2020-03-19
TW201843151A (zh) 2018-12-16
MA49884A (fr) 2020-06-24
JOP20190209A1 (ar) 2019-09-12
CA3055258A1 (en) 2018-09-20
US20210347775A1 (en) 2021-11-11
IL269272A (en) 2019-11-28
NI201900094A (es) 2020-03-18
MX2019010898A (es) 2019-11-07
CN110431139B (zh) 2022-07-05
PH12019502086A1 (en) 2020-03-09
JP2020514344A (ja) 2020-05-21
EA038233B1 (ru) 2021-07-28
AU2018234985B2 (en) 2020-04-02
EA201992090A1 (ru) 2020-03-06
SG11201908065YA (en) 2019-09-27
CR20190429A (es) 2019-11-12
EP3596076A1 (en) 2020-01-22
KR20190129923A (ko) 2019-11-20

Similar Documents

Publication Publication Date Title
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
NI202000099A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
NI201900094A (es) COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
UY38625A (es) Compuestos y su uso en el tratamiento del cáncer
CL2022001337A1 (es) Derivados de piridopirimidinona como antagonistas de ahr
CO2018010951A2 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
CL2017003025A1 (es) Derivados(1,2-b)(1,2,4)de imidazotriazina como agentes antiparasitarios.
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos